Glaxo, Astellas duel for new place in anemia market; Novo Nordisk opens new U.S. HQ;

@FiercePharma: U.K. likely to pay for Avastin despite another NICE rejection. More | Follow @FiercePharma

@EricPFierce: Some popular drugs like Pradaxa, Prolia to be put through despised German price shredding formula. Story | Follow @EricPFierce

> Novo Nordisk ($NVO) opened a new U.S. headquarters in Plainsboro, N.J. Release

> Both GlaxoSmithKline ($GSK) and Japan's Astellas Pharma are working on pills for anemia to break into an $8 billion market targeted at injectable erythropoietin. Story

> Europe is looking to add environmental impact studies to evaluations of drugs. Report

> A watchdog group is asking regulators to look at the entire class of GLP-1 inhibitors for diabetes because of their link to a high number of cases of pancreatitis and pancreatic cancer. Report

> The South Korea-based biotech Celltrion has followed other drug developers in nixing late-stage development of a biosimilar version of Rituxan. Story

Medical Device News

@FierceMedDev: Hamburg: FDA is a bargain for taxpayers. Story | Follow @FierceMedDev

 @DamianFierce: LabCorp is slimming down and diversifying to stay profitable in a tough testing market. More | Follow @DamianFierce

> Intuitive Surgical's Q1 soars, despite da Vinci robot lawsuits. Article

> Covidien recalls ventilator batteries over failure risk. More

> Device company VC funding continues its plunge. Report

Biotech News

@FierceBiotech: Hear from top execs at Janssen talk about drug R&D, industry's drug pipeline efforts. More | Follow @FierceBiotech

@RyanMFierce: Biotech rattled as Q1 first-time VC deals plunge to 18-year low. News | Follow @RyanMFierce

> Pharma giants' oral EPO alternatives could cater to dopers. More

> Vertex skyrockets on positive Ph2 combo study in cystic fibrosis. Story

> Epizyme hits the biotech IPO queue with rapid R&D plan for cancer drugs. Report

And Finally... Cubist Pharmaceuticals ($CBST), which has said it is shooting for $2 billion in sales by 2017, reported its first quarter net income fell more than 80% after it paid $15 million to buy the rights to market an experimental antibiotic in more countries. Story

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.